Pazopanib in Imatinib Refractory or Intolerant Gastrointestinal Stromal Tumors (GIST)
Status:
Terminated
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
This study is being done to gather information about the safety (any harmful effects) and
effectiveness (usefulness) of Pazopanib in the treatment of Gastrointestinal Stroma Tumors
(GIST) that cannot be treated by surgery or has spread to other organs. The Food and Drug
Administration (FDA) have approved Pazopanib for the treatment of advanced kidney cancer but
it is not approved for the treatment of GIST. The investigators hope to learn about the
safety and usefulness (effectiveness) of Pazopanib for patients with GIST.
Primary Objective:
Non-progression rate based on RECIST criteria (CR+PR+SD)
Secondary Objectives:
- Response per Choi criteria
- 6 month progression-free survival
- Safety and tolerability